Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora, Inc. reported that director Lorence H. Kim, M.D., resigned from its Board of Directors effective immediately on August 13, 2026, following the conclusion of the Board’s quarterly meeting.
The company states that Dr. Kim’s decision is connected to his appointment as Chief Financial Officer of Commonwealth Fusion Systems, Inc. and his need to devote additional time to those professional responsibilities. Dr. Kim advised that his resignation is not due to any disagreement regarding Cencora’s operations, policies, or practices. The company expressed appreciation for his dedicated service.
Cencora, Inc. reports that beginning July 1, 2026, certain Walgreens volume that had been serviced separately from the existing prime vendor agreement began moving outside Cencora. The company states that the prime vendor agreement, which it describes as constituting the vast majority of its Walgreens business, remains unchanged.
Cencora also reaffirms its previously issued fiscal 2026 adjusted diluted EPS guidance in the range of $17.75 to $17.95. The company includes cautionary language that these are forward-looking statements based on current expectations and subject to risks and uncertainties described in its periodic reports.
Cencora, Inc. (symbol COR) filed a notice of proposed sales of common stock under Rule 144. The filing lists up to 20,000 shares of common stock held at Fidelity Brokerage Services LLC, with an aggregate market value of $6,333,096.30, to be sold on the NYSE on or after August 6, 2026. The schedule references underlying share sources including restricted stock vesting and a stock option exercise on various dates in late 2025 and March 2026.
Cencora, Inc. delivered higher results for the quarter and nine months ended June 30, 2026. Revenue reached $84,754,837 (in thousands) for the quarter and $249,042,769 (in thousands) for nine months, up 5.1% and 4.8% year over year. Net income attributable to Cencora rose to $763,518 (in thousands) in the quarter and $2,964,497 (in thousands) for nine months, with diluted EPS of $3.94 and $15.21, above prior-year levels.
Growth was driven mainly by U.S. Healthcare Solutions, including strong demand for GLP-1 diabetes and weight-loss therapies, and contributions from the RCA and OneOncology acquisitions. OneOncology added $820.0 million of revenue since closing. Operating cash flow was $1,687,530 (in thousands), while heavy acquisition spending produced investing outflows of $5,414,365 (in thousands) and lifted long-term debt to $11,444,086 (in thousands).
Cencora continues to manage large legal and portfolio actions. An opioid-related liability of $4.2 billion is payable over 13 years, but 2026 results include a $160.9 million litigation credit and an $86.8 million insurance recovery from a derivative settlement. The MWI Animal Health business, with $3,836,060 (in thousands) of assets held for sale, is under an FTC-reviewed merger, and a $165.7 million goodwill impairment was recorded on a divested consulting unit.
Cencora, Inc. amended and restated its multi-currency senior unsecured revolving credit facility, increasing aggregate lender commitments to $7.0 billion from $5.5 billion and extending the maturity to July 2031. Borrowings accrue interest at margins ranging from 69.5 to 110 basis points over benchmark rates and 0 to 10 basis points over alternate base and Canadian prime rates, with covenants including a maximum financial leverage ratio and customary events of default.
The company also executed an Omnibus Amendment to its receivables securitization structure, reducing the Receivables Securitization Facility commitment from $1.5 billion to $1.0 billion while increasing the accordion feature to $1.0 billion and adding a new uncommitted purchaser. Accounts receivable originated by ABDC and ASD are sold to ARFC, which in turn sells interests to purchaser groups, with Cencora acting as performance guarantor, providing an additional liquidity and funding source for ongoing business needs.
Cencora reported strong fiscal third-quarter 2026 results, with revenue of $84.8 billion, up 5.1% year-over-year, and gross profit of $3.6 billion, up 24.1%. GAAP diluted EPS rose to $3.94 from $3.52, while adjusted diluted EPS increased to $4.48 from $4.00.
Operating income grew 29.1% to $1.1 billion, driven by higher margins in U.S. Healthcare Solutions after the February 2026 OneOncology acquisition and growth in specialty and GLP-1 products, partly offset by higher operating expenses and a 72.0% rise in net interest expense to $140.7 million. Net income attributable to Cencora was $763.5 million. For the first nine months, revenue increased 4.8% and diluted EPS reached $15.21 versus $9.70, reflecting a $1.1 billion gain on remeasurement of the prior OneOncology stake.
Outlook and capital allocation were updated: fiscal 2026 adjusted EPS guidance was raised to $17.75–$17.95; adjusted operating income is projected to grow 13–14%, revenue 4–6%, and adjusted free cash flow about $3.0 billion with approximately $900 million in capital expenditures. Cencora repurchased $1 billion of shares in the quarter and declared a $0.60 per-share dividend payable August 31, 2026.
NALLY DENNIS M reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. reported that director Dennis M. Nally received a grant of 113 shares of common stock on July 31, 2026 at $311.34 per share, issued in lieu of a $35,000 quarterly cash retainer under the Non-Employee Director Compensation Program. After this award, he directly holds 13,188 shares.
Cooper Ellen reported acquisition or exercise transactions in this Form 4 filing.
Cencora director Ellen Cooper received a grant of 97 restricted stock units on July 31, 2026, in lieu of a $30,000 quarterly cash retainer under the Non-Employee Director Compensation Program. The award equates to $311.34 per share, bringing her direct holdings to 893 shares, with receipt deferred until she leaves the board.
Tyler Lauren M reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. reported that director Lauren M Tyler received a grant of 97 restricted stock units representing common stock on 2026-07-31 at a reference price of $311.34 per share. The award was granted in lieu of a $30,000 quarterly cash retainer under the Non-Employee Director Compensation Program, with receipt of shares deferred until cessation of service. Following the grant, Tyler directly holds 4,456 shares of common stock.
Cencora, Inc. Executive Vice President Silvana Battaglia acquired 58.2040 shares of common stock on 2026-06-30 at $240.5330 per share through the company’s Employee Stock Purchase Plan, as described under Rule 16b-3(c) and 16b-3(d). Following this compensation-related acquisition, she directly holds 23,624.0120 common shares.